Cadrenal Therapeutics, Common Stock Current Liabilities
| CVKD Stock | 14.01 0.49 3.38% |
Cadrenal Therapeutics, Common fundamentals help investors to digest information that contributes to Cadrenal Therapeutics,'s financial success or failures. It also enables traders to predict the movement of Cadrenal Stock. The fundamental analysis module provides a way to measure Cadrenal Therapeutics,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cadrenal Therapeutics, stock.
The current year's Total Current Liabilities is expected to grow to about 864.5 K, whereas Non Current Liabilities Total is forecasted to decline to 0.00. Cadrenal |
Cadrenal Therapeutics, Common Company Current Liabilities Analysis
Cadrenal Therapeutics,'s Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Cadrenal Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Cadrenal Therapeutics, is extremely important. It helps to project a fair market value of Cadrenal Stock properly, considering its historical fundamentals such as Current Liabilities. Since Cadrenal Therapeutics,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cadrenal Therapeutics,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cadrenal Therapeutics,'s interrelated accounts and indicators.
Click cells to compare fundamentals
Cadrenal Current Liabilities Historical Pattern
Today, most investors in Cadrenal Therapeutics, Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cadrenal Therapeutics,'s growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Cadrenal Therapeutics, current liabilities as a starting point in their analysis.
Cadrenal Therapeutics, Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
In accordance with the recently published financial statements, Cadrenal Therapeutics, Common has a Current Liabilities of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
Cadrenal Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cadrenal Therapeutics,'s direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cadrenal Therapeutics, could also be used in its relative valuation, which is a method of valuing Cadrenal Therapeutics, by comparing valuation metrics of similar companies.Cadrenal Therapeutics, is currently under evaluation in current liabilities category among its peers.
Cadrenal Therapeutics, ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Cadrenal Therapeutics,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Cadrenal Therapeutics,'s managers, analysts, and investors.Environmental | Governance | Social |
Cadrenal Fundamentals
| Return On Equity | -1.25 | ||||
| Return On Asset | -0.71 | ||||
| Current Valuation | 18.88 M | ||||
| Shares Outstanding | 1.66 M | ||||
| Shares Owned By Insiders | 34.00 % | ||||
| Number Of Shares Shorted | 39.48 K | ||||
| Price To Book | 6.81 X | ||||
| EBITDA | (8.34 M) | ||||
| Net Income | (8.36 M) | ||||
| Total Debt | 21.35 K | ||||
| Book Value Per Share | 3.09 X | ||||
| Cash Flow From Operations | (3.53 M) | ||||
| Short Ratio | 0.65 X | ||||
| Earnings Per Share | (6.73) X | ||||
| Target Price | 35.67 | ||||
| Market Capitalization | 23.24 M | ||||
| Total Asset | 8.52 M | ||||
| Retained Earnings | (15.07 M) | ||||
| Working Capital | 7.67 M | ||||
| Net Asset | 8.52 M |
About Cadrenal Therapeutics, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cadrenal Therapeutics, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cadrenal Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cadrenal Therapeutics, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cadrenal Therapeutics, is a strong investment it is important to analyze Cadrenal Therapeutics,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cadrenal Therapeutics,'s future performance. For an informed investment choice regarding Cadrenal Stock, refer to the following important reports:Check out Cadrenal Therapeutics, Piotroski F Score and Cadrenal Therapeutics, Altman Z Score analysis. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cadrenal Therapeutics,. If investors know Cadrenal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cadrenal Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.73) | Return On Assets (0.71) | Return On Equity (1.25) |
The market value of Cadrenal Therapeutics, is measured differently than its book value, which is the value of Cadrenal that is recorded on the company's balance sheet. Investors also form their own opinion of Cadrenal Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Cadrenal Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cadrenal Therapeutics,'s market value can be influenced by many factors that don't directly affect Cadrenal Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cadrenal Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Cadrenal Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cadrenal Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.